Duchenne muscular dystrophy is a rare genetic condition that causes progressive muscle weakness, impacting movement, respiratory health and cardiac function. It is caused by mutations in the dystrophin gene, which leave muscles more vulnerable to damage over time. We're committed to advancing innovative science to address unmet needs for individuals and families living with #Duchenne. Learn more below. #RareDisease

At #ESGCT2026, we'll share seven presentations spanning our Duchenne program and platform technologies, including POLARIS-101™, our next-generation, engineered myotropic capsid. Read our press release and visit our posters to learn about our work in #Duchenne, POLARIS-101 and our commitment to advancing genetic medicines. investors.solidbio.com/news-…

Next week, we're attending the 2026 Friedreich's Ataxia Symposium hosted by Friedreich's Ataxia Research Alliance (FARA) and the Friedreich’s Ataxia Center of Excellence at Children’s Hospital of Philadelphia. Matt Harmelink, Neuromuscular Therapeutic Area Head, will join the FA Drug Development Pipeline Panel Discussion to speak about our work in FA and our Phase 1b FALCON clinical trial. Stop by our exhibit table if you're attending, or register to join the panel virtually: curefa.org/get-involved/educ… #FACommunity #RareDisease

We recently joined @defeatduchenne's 2026 Family Forum, which focused on fostering education and connection for individuals and families living with Duchenne. We're proud to support initiatives that empower families with knowledge, foster connections and dialogue, and build community. #Duchenne #RareDisease

We're committed to shaping the future of gene therapy. POLARIS-101™, our proprietary next-generation, muscle-tropic capsid, has potential to transform the safe, efficient and scalable delivery of genetic medicines across neuromuscular and cardiac diseases. With our #SolidInside approach, we're building a suite of technologies available for partnership and out-licensing to help developers accelerate innovation. Learn more below or on our website: solidbio.com/partners/

At the Annual World Muscle Society Congress, we're presenting six posters across our neuromuscular portfolio highlighting our work in Duchenne, Friedreich's ataxia and our proprietary POLARIS-101™ capsid, which is designed to enable safe and effective gene therapy delivery and has shown encouraging clinical signals in #Duchenne. We look forward to connecting with leading global experts to advance scientific progress in rare neuromuscular diseases. #WMS2026 #SolidInside

We look forward to attending the Annual Neuromuscular Study Group Scientific Meeting, where we'll share two posters highlighting our work in #Duchenne, including our POLARIS-101™ capsid and our Phase 1/2 INSPIRE DUCHENNE study. We value opportunities to engage with researchers, clinicians and advocates working to shape the future of patient care. #SolidInside #RareDisease

In honor of #WorldDuchenneAwarenessDay, we joined @JettFoundation at the Gals for Cal women's triathlon, coming together with the community to raise awareness, recognize progress and advance a future that is #StrongerThanDuchenne. Every day, we're proud to support greater access to care, continued research and inclusive experiences for individuals living with Duchenne. #WDAD2026

$SLDB: Today, our CEO Bo Cumbo will participate in a fireside chat at the @HCWCO 28th Annual Global Investment Conference. Join us live or watch the replay here: investors.solidbio.com/news-…

$SLDB: This week, our CEO Bo Cumbo and CMO Gabriel Brooks will participate in fireside chats at the @Official_Cantor Global Healthcare Conference and the @Citi Biopharma Back to School Summit. Tune in live or watch the replay here: investors.solidbio.com/news-…

Today on #WorldDuchenneAwarenessDay, we reflect on the profound impact that access to care, resources, scientific breakthroughs and opportunities can have for individuals and families affected by #Duchenne. We remain committed to advancing research and innovation, working alongside the Duchenne community in pursuit of meaningful progress. #WDAD2026 #RareDisease

Improving access for individuals living with Duchenne is about more than healthcare. It's about creating opportunities to fully participate in their communities and engage in activities they love. As we approach #WorldDuchenneAwarenessDay, we reflect on the importance of expanding access, and we stand with the Duchenne community in raising awareness, driving innovation and removing barriers. Read more from Annie Ganot, Solid Co-Founder, SVP Patient Advocacy and Duchenne mom. #WDAD2026 #RareDisease

$SLDB: We're looking forward to attending several investor conferences this month, where members of management will join fireside chats to discuss Solid's strategy and recent progress. Read more: investors.solidbio.com/news-…

Ahead of #WorldDuchenneAwarenessDay on September 7, we're joining the global Duchenne community in recognizing this year's theme, "Access Changes Lives." Access is a fundamental driver of better outcomes for individuals living with #Duchenne. This year's theme focuses on removing barriers to knowledge, research and support, helping people make informed decisions and creating opportunities to live full lives. Learn more from @worldduchenne: worldduchenne.org/world-duch… #WDAD2026 #RareDisease

Recently, we joined @PPDCRO at their GMP Lab in Middleton, WI, for a discussion with patient advocates in the #FriedreichsAtaxia (FA) community. This panel featured firsthand perspectives from those impacted by FA and insights into our work in FA, fostering a deeper understanding of the patient and caregiver experience. We're proud to be part of important conversations that strengthen collaboration and advance our shared goal of improving outcomes for people in need. Thank you to Sam, Aiden and Rachel for sharing your stories! #FACommunity #RareDisease